XRCC6 and neoplasm: Moreover, immunohistochemistry (IHC) analysis of tumor tissues confirmed that olaparib increased DNA damage in tumors with CXorf56-knockdown; the difference in γH2AX expression between CXorf56-knockdown and negative control cells was eliminated by Ku70 knockdown (Fig. 5L, M).